|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 225.00 EUR | -1.83% |
|
-10.32% | -5.70% |
| Aug. 05 | UCB Publishes Results Of Post Hoc Data Analysis Of Fintepla In Patients With Lennox-Gastaut Syndrome | CI |
| Aug. 01 | UCB SA, H1 2026 Earnings Call, Jul 30, 2026 |
Chart: Technical Analysis
Technical analysis trends
| Short Term | Mid-Term | Long Term | |
|---|---|---|---|
| Trend | Bearish | Bearish | Neutral |
| Resistance | 243 | 250.9 | 279.5 |
| Spread/Res. | -7.41% | -10.32% | -19.50% |
| Spread/Supp. | +3.69% | +3.69% | +14.27% |
| Support | 217 | 217 | 196.9 |
MarketScreener's Technical Analysis Ratings
| Short Term Timing | |
|---|---|
| Middle Term Timing | |
| Long Term Timing | |
| RSI | |
| Bollinger Spread | |
| Unusual Volumes |
- Stock Market
- Stocks
- UCB Stock
- Charts UCB
Select your edition
All financial news and data tailored to specific country editions
